← All trials
NCT04982380
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2021
- Primary completion
- Jul 31, 2022
- Completion date
- Jul 31, 2022
- First posted
- Jul 29, 2021
- Last posted
- Jul 29, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Zhengzhou UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Inner Mongolia Medical UniversityCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Chinese Academy of Medical SciencesCollaborator
- Chengde Medical UniversityCollaborator
- Hangzhou Grand Biologic Pharmaceutical, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.